Aurobindo Pharma Pioglitazone Tablets 45mg Recall: Superpotent Tablet Risk
Aurobindo Pharma recalls 45mg Pioglitazone tablets with failed specifications that may be superpotent. Consumers should check NDC 57237-221-05 and batch numbers PF4520028A/B for affected products.
Recall notice
Superpotent and Failed Tablet/Capsule Specifications
Contact the company
What happened, in plain English
Aurobindo Pharma is recalling 45mg Pioglitazone tablets that may have failed specifications, making them superpotent. This could cause harmful effects if taken as directed. Read more at govinfonow.com/recall/35414-aurobindo-pharma-pioglitazone-tablets-45mg-recall-superpotent-tablet-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/35414-aurobindo-pharma-pioglitazone-tablets-45mg-recall-superpotent-tablet-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0450-2022
Cite this page
“Aurobindo Pharma Pioglitazone Tablets 45mg Recall: Superpotent Tablet Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35414-aurobindo-pharma-pioglitazone-tablets-45mg-recall-superpotent-tablet-risk. Based on FDA recall #D-0450-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0450-2022%22&limit=1).
Why it’s dangerous
The tablets may have failed specifications, meaning they could be superpotent. This could lead to harmful effects if taken as directed, potentially causing serious health issues.
Who’s affected
People who own or use the recalled 45mg Pioglitazone tablets with NDC 57237-221-05 and batch numbers PF4520028A or PF4520028B are affected. Those taking the medication for diabetes are most at risk.
How to tell if you have this one
Check for NDC 57237-221-05 on the product label. The batch numbers are PF4520028A or PF4520028B with an expiration date of November 2022.
- Brand
Aurobindo Pharma- Category
Drug
What to do — step by step
Check Product Details
Look for NDC 57237-221-05 and batch numbers PF4520028A or PF4520028B on the tablet packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 23 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Aurobindo Pharma recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0450-2022 (December 29, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0450-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.